(4R,5S)/(4S,5R)-4,5-Bis(4-hydroxyphenyl)-2-imidazolines: Ligands for the estrogen receptor with a novel binding mode

Journal of Medicinal Chemistry

Volumn 45, Issue 16, 2002, Pages 3356-3365

  Gust, Ronald ^a   Keilitz, Roland ^a   Schmidt, Kathrin ^a   Von Rauch, Moriz ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 (2 CHLORO 4 HYDROXYPHENYL) 5 (2,6 DICHLORO 4 HYDROXYPHENYL) 2 IMIDAZOLINE; 4 (2,6 DICHLORO 4 HYDROXYPHENYL) 5 (2 FLUORO 4 HYDROXYPHENYL) 2 IMIDAZOLINE; 4,5 BIS(2 CHLORO 4 HYDROXYPHENYL) 2 IMIDAZOLINE; 4,5 BIS(2 FLUORO 4 HYDROXYPHENYL) 2 IMIDAZOLINE; 4,5 BIS(4 HYDROXY 2 IODOPHENYL) 2 IMIDAZOLINE; 4,5 BIS(4 HYDROXY 2 METHYLPHENYL) 2 IMIDAZOLINE; 4,5 BIS(4 HYDROXYPHENYL) 2 IMIDAZOLINE; 4,5 BIS(4 HYDROXYPHENYL) 2 IMIDAZOLINE DERIVATIVE; ASPARTIC ACID; BORON DERIVATIVE; DIETHYLSTILBESTROL; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ETHANE; ETHYLENEDIAMINE DERIVATIVE; FORMIC ACID DERIVATIVE; HISTIDINE; IMIDAZOLINE DERIVATIVE; LIGAND; LUCIFERASE; PIPERAZINE; RALOXIFENE; STILBENE; UNCLASSIFIED DRUG;

AGONIST; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; BINDING SITE; CANCER CELL; CHEMICAL REACTION; CONTROLLED STUDY; DRUG CLASSIFICATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; GENE ACTIVATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HYDROPHOBICITY; MOLECULAR MODEL; PHARMACOPHORE; SPECTROSCOPY;

ANIMALS; BINDING SITES; BINDING, COMPETITIVE; CATTLE; CELLS, CULTURED; CYTOSOL; FEMALE; IMIDAZOLES; LIGANDS; LUCIFERASES; LUMINESCENT MEASUREMENTS; MODELS, MOLECULAR; RADIOLIGAND ASSAY; RECEPTORS, ESTROGEN; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED; UTERUS;

EID: 0036681599     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020809h     Document Type: Article

References (37)

1. Estrogens
2. Skeletal effects of estrogens
3. The vascular protective effects of estrogen
4. Estrogen inhibits the vascular injury response in estrogen receptor deficient mice
5. Oestrogenic activity of alkylated stilboestrols
6. Molecular structure in relation to oestrogenic activity. Compounds without a phenanthrene nucleus
7. Structure-activity relationships for a large diverse set of natural, synthetic, and environmental estrogens
8. Molecular basis of agonism and antagonism in the oestrogen receptor
9. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen
10. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist
11. The medical chemistry of nonsteroidal antiestrogens: A review
12. Artifical Estrogens
13. Synthetic estrogens and the relation between their structure and activity
14. Novel structural templates for estrogen-receptor ligands and prospects for combinatorial synthesis of estrogens
15. Diaminobenzo[b]thiophene derivatives as a novel class of active site directed thrombin inhibitors. 5. Potency, efficacy, and pharmacokinetic properties of modified C-3 side chain derivatives
16. Pyrazole Ligands: Structure - Affinity/activity relationships and estrogen receptor-selective agonists
17. Synthesis and biological evaluation of a novel series of furans: Ligands selective for estrogen receptor α
18. Furans with basic side chains: Synthesis and biological evaluation of a novel series of antagonists with selectivity for the estrogen receptor alpha
19. Investigations of new lead structures for the design of selective estrogen receptor modulators
20. Synthesis, structural evaluation, and estrogen receptor interaction of 2,3-diphenylpiperazines
21. The synthesis of 1,4-substituted imidazoles
22. Vicinal proton coupling in nuclear magnetic resonance
23. Aqua[1-(2,6-dichloro-4-hydroxyphenyl)-2-phenylethylenediamine] sulfatoplatinum(II) complexes with variable substituents in the 2-phenyl ring. 1. Synthesis and antitumor and estrogenic properties
24. Structure activity studies on leaving group derivatives of [meso- 1,2-bis-(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]platinum-(II)
25. Antiestrogens. Synthesis and evaluation of mammary tumor inhibiting activity of 1,1,2,2-tetraalkyl-1,2-diphenylethanes
26. Effect of growth factors on estrogen receptor mediated gene expression
27. 1-Benzyl-2-phenylindole- and 1,2-diphenylindole-based antiestrogens. Estimation of agonist and antagonist activities in transfection assays
28. Ring-substituted [1,2-bis(4-hydroxyphenyl)ethylenediamine]dichloroplatinum(II) complexes: Compounds with a selective effect on the hormone-dependent mammary carcinoma
29. Aqua-[1-(2,6-dichloro-4-hydroxyphenyl)-2-phenylethylenediamine] sulfatoplatinum(II) complexes with variable substituents in the 2-phenyl ring. Part II: Correlation of molecular structure and estrogenic activity of breast and prostate cancer inhibiting [erythro-1-(2,6-dichloro-4-hydroxyphenyl)-2-(2-halo-4-hydroxyphenyl) ethylenediamine]platinum(II) Complexes
30. 1-(2,6-dichloro-4-hydroxyphenyl)-2-phenylethanes-new biological response modifiers for the therapy of breast cancer. Synthesis and evaluation of estrogenic/antiestrogenic properties
31. The estrogen receptor: A structure based approach to the design of new specific hormone-receptor combinations
32. The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor
33. Control of the estrogen-like action of the tamoxifen-estrogen receptor complex by the surface amino acid at position 351
34. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351
35. Molecular classification of estrogens
36. Synthesis, conformational studies, and investigations on the estrogen receptor binding of [R/S-1-(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]platinum(II) complexes
37. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding